Skip to main content Skip to navigation
BUV661 Mouse Anti-Human Delta-Like Protein 4
Product Details
Down Arrow Up Arrow


BD OptiBuild™
DLL4; Delta-like 4; DL4; Delta ligand 4; Delta4; Notch ligand DLL4
Human (Tested in Development)
Mouse IgG1, κ
Human Delta-Like Protein 4 Recombinant Protein
Flow cytometry (Qualified)
0.2 mg/ml
AB_2874109
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV661 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 661 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
749869 Rev. 4
Antibody Details
Down Arrow Up Arrow
MHD4-46

The MHD4-46 monoclonal antibody specifically binds to Delta-Like Protein 4 which is also known as Delta4, DLL4, and DL4. Delta-Like Protein 4 is a type 1 transmembrane glycoprotein which belongs to the Delta/Serrate/Jagged Family of Notch receptor ligands. The Notch family of transmembrane receptors and their ligands play key roles in various developmental and postnatal processes by controlling cell-fate decisions. Delta-Like Protein 4 is expressed by vascular endothelial cells within certain normal tissues and tumors. It signals through Notch1 and Notch 4 Receptors and plays a critical role in vascular development and homeostasis. Delta-Like Protein 4 expression is upregulated in response to vascular endothelial growth factor (VEGF) and regulates endothelial cell proliferation during vascular sprouting. Delta-Like Protein 4 is also expressed by activated human monocytes and dendritic cells that have been stimulated with proinflammatory activators such as lipopolysaccharide. Recent evidence suggests that Delta-Like Protein 4 may contribute to the T cell potential of CD34+ cells and to the growth of various tumors, and promote tumor cell infiltration.

The antibody was conjugated to BD Horizon™ BUV661 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 661-nm. BD Horizon Brilliant BUV661 can be excited by the ultraviolet laser (355 nm) and detected with a 670/25 filter and a 630 nm LP.  Due to cross laser excitation of this dye, there may be significant spillover into channels detecting APC-like emissions (eg, 670/25-nm filter).

    

Due to spectral differences between labeled cells and beads, using BD™ CompBeads can result in incorrect spillover values when used with BD Horizon BUV661 reagents. Therefore, the use of BD CompBeads or BD CompBeads Plus to determine spillover values for these reagents is not recommended. Different BUV661 reagents (eg, CD4 vs. CD45) can have slightly different fluorescence spillover therefore, it may also be necessary to use clone-specific compensation controls when using these reagents.

749869 Rev. 4
Format Details
Down Arrow Up Arrow
BUV661
The BD Horizon Brilliant™ Ultraviolet 661 (BUV661) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 660-nm. BUV661, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 660-nm (e.g., 670/25 bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BUV661
Ultraviolet 355 nm
350 nm
660 nm
749869 Rev.4
Citations & References
Down Arrow Up Arrow

Development References (10)

  1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development.. Science. 1999; 284(5415):770-6. (Biology). View Reference
  2. Fung E, Tang SM, Canner JP, et al. Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation. 207; 115(23):2948-2956. (Biology). View Reference
  3. Gurney A, Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc Cell. 2011; 3(18):21. (Biology). View Reference
  4. Herr F, Schreiner I, Baal N, Pfarrer C, Zygmunt M. Expression patterns of Notch receptors and their ligands Jagged and Delta in human placenta. Placenta. 2011; 32(8):554-563. (Biology). View Reference
  5. Lefort N, Benne C, Lelievre JD, et al. Short exposure to Notch ligand Delta-4 is sufficient to induce T-cell differentiation program and to increase the T cell potential of primary human CD34+ cells. Exp Hematol. 2006; 34(12):1720-1729. (Biology). View Reference
  6. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 2001; 69(2-3):135-144. (Biology). View Reference
  7. Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H. Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther. 2012; 14(2):R45-R58. (Immunogen: Flow cytometry). View Reference
  8. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000; 14:1313-1318. (Biology). View Reference
  9. Shutter JR, Scully S, Fan W, et al. Molecular cloning of delta-4, a new mouse and human Notch ligand. J Biochem (Tokyo). 2001; 129(1):27-34. (Biology). View Reference
  10. Wakui M, Nakano K, Matsushita S. Notch ligand mRNA levels of human APCs predict Th1/Th2-promoting activities. Biochem Biophys Res Commun. 2007; 358(2):596-601. (Biology). View Reference
View All (10) View Less
749869 Rev. 4

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.